Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
120.30    1.40 (1.18%)
Bid:
119.60
Ask:
119.90
Spread: 0.30 (0.251%)
Market Cap: £1.17b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

Agreement

1 Apr 2022 07:00

RNS Number : 8618G
Oxford Nanopore Technologies plc
01 April 2022
 

1 April 2022

Oxford Nanopore Technologies plc

Entry into settlement agreement with Department of Health and Social Care

The Department of Health and Social Care (DHSC) and Oxford Nanopore Technologies plc (ONT) reached an amicable resolution of the dispute relating to the contract dated 30 July 2020 for the supply of certain LamPORE™ devices and testing kits and associated services by ONT to DHSC. DHSC and ONT entered into a settlement agreement without any admission of liability, which included agreement as to the contract being brought to an end and includes a payment of £50 million in full of amounts due to ONT under the contract.

ONT expects the payment to be treated as non-recurring COVID-19 testing revenue during the fiscal year ended 31 December 2022. Therefore, ONT's prior guidance for Life Science Research Tools revenue in 2022 remains unchanged.

[ENDS]

Enquiries:

Investors

ir@nanoporetech.com 

Media

media@nanoporetech.com

oxfordnanoporetechnologies@tulchangroup.com

This announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU no. 596/2014), which forms part of English law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREANDFDAAAEFA
Date   Source Headline
1st Nov 20244:00 pmRNSIssue of Capital and Total Voting Rights
16th Oct 202412:00 pmRNSFounder LTIP - Director/PDMR Notification
15th Oct 20248:00 amRNSHolding(s) in Company
15th Oct 20247:00 amRNSIssue of Equity and Total Voting Rights
14th Oct 202410:00 amRNSAdmission to Trading on the London Stock Exchange
11th Oct 20244:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Oct 20248:00 amRNSNew issue in connection with LTIP awards
8th Oct 20247:00 amRNSNotice of intention to transfer listing category
7th Oct 20246:15 pmRNSBlock Listing Interim Review
2nd Oct 20249:00 amRNSIssue of Equity and Total Voting Rights
1st Oct 20247:00 amRNSDaniel Mahony appointed as Non-Executive Director
13th Sep 20244:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Sep 20247:00 amRNSSeeks discovery into expected breach of contract
3rd Sep 202412:00 pmRNSIssue of Equity and Total Voting Rights
3rd Sep 202412:00 pmRNSHolding(s) in Company
3rd Sep 20247:00 amRNSInterim results for the 6 months ended 30 June 24
30th Aug 20242:00 pmRNSNotice of Interim Results Presentation
20th Aug 20243:00 pmRNSHolding(s) in Company
15th Aug 20247:00 amRNSHolding(s) in Company
14th Aug 20247:00 amRNSHolding(s) in Company
13th Aug 20245:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
9th Aug 20245:30 pmRNSHolding(s) in Company
9th Aug 20243:00 pmRNSDirector Declaration
7th Aug 20245:30 pmRNSHolding(s) in Company
7th Aug 20242:00 pmRNSHolding(s) in Company
5th Aug 202412:30 pmRNSAdmission of Ordinary Shares & Total Voting Rights
1st Aug 20245:30 pmRNSIssue of Equity and Total Voting Rights
1st Aug 20247:00 amRNSInvestment from Novo Holdings and Equity Issue
31st Jul 20244:58 pmRNSInvestment from Novo Holdings and proposed placing
24th Jul 20247:00 amRNSHalf Year Trading Update
16th Jul 20247:00 amRNSAppointment of corporate broker
11th Jul 20244:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
3rd Jul 20245:30 pmRNSFounder LTIP - Director/PDMR Notification
1st Jul 20244:30 pmRNSTotal Voting Rights
28th Jun 20244:30 pmRNSFounder LTIP - Director/PDMR Notification
21st Jun 20245:33 pmRNSIssue of Equity and Total Voting Rights
21st Jun 202410:00 amRNSAdmission to Trading on the London Stock Exchange
19th Jun 20247:00 amRNSIssue of Equity
11th Jun 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Jun 20244:00 pmRNSResult of AGM; Director Responsibilities
7th Jun 20244:00 pmRNSPDMR/PCA Notification
3rd Jun 20244:00 pmRNSIssue of Equity and Total Voting Rights
23rd May 20248:00 amRNSLondon Calling Technology Update
13th May 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st May 20245:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20247:00 amRNSDirector/PDMR Shareholding
30th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
12th Apr 20241:00 pmRNSStudy unlocks insights into disease and longevity
12th Apr 202412:00 pmRNSLTIP and DBP; Director/PDMR Notification
11th Apr 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.